Avacta Revenue and Competitors
Estimated Revenue & Valuation
- Avacta's estimated annual revenue is currently $47M per year.
- Avacta's estimated revenue per employee is $155,000
Employee Data
- Avacta has 303 Employees.
Avacta's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Executive | Reveal Email/Phone |
2 | CFO | Reveal Email/Phone |
3 | VP, Head Biology | Reveal Email/Phone |
4 | VP Chemistry | Reveal Email/Phone |
5 | Head QA/ RA | Reveal Email/Phone |
6 | Chief Commercial Officer, Diagnostics | Reveal Email/Phone |
7 | Group Communications Director | Reveal Email/Phone |
8 | Chief Scientific Officer (Diagnostics) | Reveal Email/Phone |
9 | Director Operations | Reveal Email/Phone |
10 | Clinical Study Manager | Reveal Email/Phone |
Avacta Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.5M | 29 | -12% | N/A | N/A |
#2 | $15.7M | 101 | 5% | N/A | N/A |
#3 | $87.9M | 405 | 25% | $292M | N/A |
#4 | $2.6M | 470 | 16% | $631.7M | N/A |
#5 | $14.9M | 96 | -8% | $81M | N/A |
#6 | $44.8M | 231 | 0% | $132.9M | N/A |
#7 | $7.6M | 49 | -37% | N/A | N/A |
#8 | $17.4M | 112 | 12% | N/A | N/A |
#9 | $334.6M | 1349 | 11% | £994.6M | N/A |
#10 | $830.2M | 5356 | 8% | N/A | N/A |
What Is Avacta?
Custom antibody alternative, Antibody alternatives, Afinnity reagents Avacta has developed Affimer technology - a revolutionary new engineered affinity protein that is an alternative to antibodies. Affimer molecules have been developed for applications in diagnostics, drug / biomarker discovery, biotech research and development and therapeutics. Find out more on our website.
keywords:N/A
N/A
Total Funding
303
Number of Employees
$47M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Avacta News
CAMBRIDGE & WETHERBY, England--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of...
(Alliance News) - Avacta Group PLC said on Wednesday it increased its shareholding in its South Korean joint venture, AffyXell Therapeutics.
Drug developer Avacta Group has announced that a milestone equity payment has been triggered resulting in an increase in the Wetherby-based...
Transformative period for both Diagnostics and Therapeutics Divisions Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces its interim resul ...
Avacta announces achievement of pre-clinical development milestone in LG Chem Life Sciences partnership 29-09-2021 Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre| ...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $96.6M | 303 | 11% | $2.4M |
#2 | $102.3M | 303 | 14% | N/A |
#3 | $7.5M | 303 | N/A | N/A |
#4 | $15M | 303 | 5% | N/A |
#5 | $35M | 303 | -60% | N/A |